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Sllmmary 
The immunological basis for atopy is currently ascribed to an inherent bias in the CD4 § T cell 
response to nonreplicating antigens presented at mucosal surfaces, resulting in dominance of the 
T helper 2 (Th2) interleukin 4 (IL-4)-producing phenotype, which favors IgE production. In 
contrast, the "normal" response to such antigens involves a predominance of interferon 3, (IFN- 
y)-producing Thl clones. This difference has been suggested to be the result of active selection 
in atopics for Th2 (and hence against Thl) clones at the time of initial antigen presentation. 
In the study below, we demonstrate that the natural immune response to inhaled protein antigens, 
particularly in animals expressing the low immunoglobulin E (IgE) responder phenotype, includes 
a major histocompatibility complex (MHC) class I-restricted CD8 + T  cell component, the 
appearance of which is associated with active suppression of IgE antibody production. Thus, 
continued exposure of rats to aerosolized ovalbumin (OVA) antigen elicits a transient IgE response, 
that is terminated by the onset of a state of apparent "tolerance" to further challenge, and this 
tolerant state is transferable to naive animals with CD8 + T  cells. Kinetic studies on in vitro 
T cell reactivity in these aerosol-exposed rats demonstrated biphasic CD4 + Th2 responses which 
terminated, together with IgE antibody production, and coincident with the appearance of MHC 
class I-restricted OVA-specific IFN-'y-producing CD8 + T cells. However, the latter were not 
autonomous in vitro and required a source of exogenous IL-2 for initial activation,  which in 
CD8 +-enriched splenocyte cultures could be provided by small numbers of contaminating  OVA- 
specific CD4 + T cells. This represents the first formal evidence for the induction of an MHC 
class I-restricted T cell response to natural mucosal exposure to an inert protein antigen, and 
is consistent  with a growing literature  demonstrating sensitization  of MHC class I-restricted 
CD8 + T cells by deliberate immunization with soluble proteins. We suggest that crossregulation 
of MHC class II-restricted CD4 + T  cells via cytokine signals generated  in parallel CD8 + T 
cell responses represents a covert and potentially important selection pressure that can shape the 
nature of host responses to nonreplicating antigens  presented  at mucosal surfaces. 
O 
ur current perception  of how the allergic phenotype 
is expressed in humans is based largely upon data im- 
plicating  IL-4  and  IFN-3,  from  different  CD4 +  T  cell 
subsets in the regulation of IgE synthesis in murine systems 
(1, 2). A key feature of these models has been the use of ac- 
tive immunization regimes comprising relatively high levels 
of antigen administered with powerful adjuvants, which elicit 
rapid high titer primary IgE responses. The success of this 
approach is undoubted, and the essential predictions  from 
the animal model, viz. the existence of compartmentalized 
CD4 + T  cell responses to ubiquitous  environmental  aller- 
gens which differ between atopics and normals, have already 
been borne out by the published  human data (3-5). 
However, the factors that determine the nature of the com- 
partmentalization of the CD4 § T cell response in different 
individuals, in particular the selection for potentially patho- 
genic CD4 § Th2 clones in atopics, remain to be defined. 
The approach taken by our laboratory to this complex ques- 
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Volume 178  September  1993  889-899 tion has followed a different route. We have reasoned that 
whereas maximal stimulation of the T  cell system via an- 
tigen plus IgE-selective adjuvants would be expected to mobi- 
lize the major cellular mechanisms that normally promote 
IgE production, hyperstimulation of this nature may also mask 
more subtle control mechanisms that function under condi- 
tions of "physiological" antigen exposure.  This is particu- 
larly the case in relation to immune responses  to inhaled 
antigens,  which  in  humans  is  associated  with  ostensibly 
adjuvant-free stimulation of the airway mucosa with nano- 
gram levels of soluble proteins. 
Accordingly, we have developed an experimental model for 
eliciting immune responses  to low levels of inhaled protein 
antigen administered by aerosol.  Our general findings (for 
reviews see references 6 and 7) indicate that this form of ex- 
posure elicits variable immune responses,  depending on the 
genetics of the animals employed, ranging from primary IgE 
responses accompanied by the expression of allergic reactivity 
through  to  the development of profound immunological 
tolerance. 
In the present study, we focus on T cell cytokine response 
in aerosol-exposed  rats, particularly during the early sensiti- 
zation phase, selecting two strains at the extremes of the IgE 
response  range. We report that whereas high and low IgE 
responder phenotype indeed segregate, respectively, with IL-4 
and IFN-3' reactivity in the T cell response, the initial source 
of T  cell-derived IFN"/are MHC class I-restricted CD8 + 
T cells, which in this model respond to soluble OVA antigen. 
Materials and Methods 
Animals.  Inbred adult (10-16 wk) Brown Norway (BN)  l and 
Wistar Albino Glaxo (WAG) rats were specific pathogen free and 
barrier housed. 
Antigen Exposure and Immunization.  The animals were exposed 
to an aerosol derived from 1% OVA (wt/vol) in saline (Grade V; 
Sigma Chemical Co., St. Louis, MO) via the Airborne Infection 
Apparatus (Tri-R. Instruments, New York, NY) for 30 rain daily, 
5 d per week for up to 2 wk, or once per week for 6 wk, as previ- 
ously described (8). Other groups of animals were chronically ex- 
posed to 1% OVA aerosol once weekly for 3-6 too, after an initial 
1-2-wk daily  exposure protocol. In one series of  experiments, animals 
of the WAG strain were administered 100 mg of OVA by garage 
on two consecutive days. Intraperitoneal immunization employed 
100 fig OVA in 10 rag aluminium hydroxide gel (AH). 
Antibody  Determinations.  Anti-OVA  IgE were measured by a 
modification of the radio-allergosorbent test (RAST) ILIA, em- 
ploying iodinated af~nity-purified  goat anti-rat IgE (9). IgG levels 
were determined as haemagglutinating antibody (HA) titers as pre- 
viously described (8). 
Antibodies.  mAbs used were provided gratis by Professor A. 
Williams and Dr. D. Mason (University of Oxford, Oxford, UK), 
as follows: OX19 (anti-rat  CD5),  W3/25 and OX35 (anti-rat 
CD4), OX8 (anti-rat CDS), OX6 (anti-MHC class II) OX18 (anti- 
t Abbreviations used in this paper: AH, aluminium  hydroxide;  BN, Brown 
Norway; HA, haemaggluting  antibody;  MFI, mean  fluorescence  intensity; 
MLN, mesenteric  lymph  node; RAST, radio-allergosorbent  test; RTLN, 
respiratory lymph node; WAG, Wistar Albino Glaxo. 
MHC class I), and OX21 (anti-human C3b) (10, 11). NDS62 (anti- 
II,-2 R) (12) was a gift from Dr. M. Dallman (John Radcliffe  Hos- 
pital, Oxford, UK). Anti-rat CD3 (13) was from Pharmingen (San 
Diego, CA).  Fluorescent staining was carried out using FITC- 
conjugated Abs, and sheep F(ab')2 anti-mouse  Ig-PE as a sec- 
ondary Ab. 
Cell Preparation.  Cell preparation from spleen, respiratory  tract 
lymph nodes (RTLN), mesenteric  nodes (MLN), and PBL employed 
standard procedures (14). 
Isolation of Lymphocyte Subsets.  Except  where specified, CD4- 
(CD8  enriched) or CDS-  (CD4  enriched) lymphocyte subsets 
were purified by negative selection, gating out cells staining with 
either anti-CD4-FITC or anti-CD8-FITC, using a cytometer (Epics 
Elite; Coulter Electronics, Hialeah, FL). Depleted cell preparations 
contained g2% stained cells (see figure legends). Splenic B cells 
were isolated by depletion of T cells utilizing a rosette depletion 
technique (15). 
Cell Cultures.  Spleen  and LN cells were cultured at 4  x  10  s 
per microplate well in RPMI containing 10-s M 2-ME plus anti- 
biotics supplemented with 5% normal rat serum and stimulated 
with 100/~g/ml OVA. Supernatants were harvested after 24 h and 
frozen at  -20~  until assayed  for cytokines, or cell proliferation 
was measured after 96 h as incorporation of [3H]thymidine into 
DNA  (14). 
Ab Blocking Experiments.  Sodium sulphate precipitated prepa- 
rations of antibodies OX21, OX18, OX6,  W3/25, and NDS62 
(5/~g/ml final concentrations) were added to cells at the initiation 
of culture (conditions as above). 
1122 Assay.  The standard bioassay  employing the CTLL-2 cell 
line was used to quantify Ib2 in culture supernatants. The stan- 
dard curve was generated from dilutions of human recombinant 
I1.,2 (Cetus Corp., Emeryville, CA). 
IFN-y Assay.  IFN-3r levels were determined by an ELISA 
method as detailed (16), and standardized against recombinant rat 
IFN-7 (all reagents were kindly provided by Dr. P. Van der Meide, 
TNO Primate Center, Rijswijk, The Netherlands). 
11_,4 Assay.  A semi-quantitative  assay  for rat Ib4 was employed 
(17) based on the striking increased expression of MHC class II 
molecules on B cells mediated by II_,4. Splenic B cells were cul- 
tured for 24 h in rlL-4 (a kind gift from Dr. A. McKnight, Univer- 
sity of Oxford) as a positive control, test supernatants, or medium 
alone. After culture, the cells were stained with OX6-FITC and 
surface MHC class II expression assessed by flow cytometry. The 
mean fluorescence  intensity (MFI) was measured  and after subtrac- 
tion of background (cells cultured in medium) the MFI of the test 
samples was expressed as a percentage of the MFI of the positive 
control. ILl0 has also been shown to stimulate MHC class II ex- 
pression on B cells (18). However, the contribution of IL-10 could 
not be assessed here because of the lack of relevant blocking Abs. 
Since IL-10 is also a product of activated Th2 (as opposed to Thl) 
cells (19), this did not potentially confound the interpretation of 
our data. 
Results 
Primary Immune Responses to OVA Antigen Administered by 
Parenteral Immunization  Versus Passive Inhalation.  Fig. I con- 
trasts the IgE and IgG responses  of BN and WAG rats to 
OVA.  Parenteral  stimulation with  antigen plus  the  IgE- 
selective adjuvant AH elicited a high-titer 1  ~ IgE response 
in the high IgE responder BN strain (Fig.  1 a) which was 
in the order of 30-fold above that seen in the low IgE re- 
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Figure  1.  IgE and lgG anti-OVA production in high (BN) and low (WAG) IgE responder rats after OVA exposure. Groups of rats (n  =  10) were 
immunized intraperitoneally with 10 mg OVA in 100 mg AH adjuvant (a and d) and bled days 9 and 21 after immunization. Further groups of animals 
(n  =  10) were exposed to 1% OVA in saline by aerosol for 30 rain daily for 10 d and bled on days 0, 3, 5, 9, and 12 during this period (b and e). 
Additional animals were exposed to 1% OVA by aerosol for 30 rain, once weekly (c and  f) for 6 wk and bled on a weekly basis as indicated. Anti-OVA 
IgE (D) and IgG (O) titers were estimated by PAST and HA, respectively, and expressed as X  •  SD. Parallel challenge of OVA-exposed animals 
with BSA in AH, revealed normal anti-BSA IgE responses (data not shown). 
sponder WAG (Fig.  1 d). IgE production terminated com- 
pletely by day 21 in the WAG, whereas the response in the 
BNs typically included a low level "persistent" component 
that continued for several weeks (data not shown). Corre- 
sponding IgG responses in the strains varied only over a two- 
fold range. 
Repeated exposure of BN rats to aerosoIized OVA either 
daily (Fig. 1 b) or weekly (Fig.  1 c) also induced significant 
IgE Ab production. However, the peak responses were ",q00- 
fold below those achieved by parenteral immunization, and 
terminated after a few weeks despite continued exposure. IgG 
responses in the aerosol-exposed  BNs, in contrast,  attained 
levels comparable with those observed with active immuni- 
zation, and remained elevated. Aerosol exposure of low IgE 
responder WAG animals (Fig. 1, e and  j) elicited smaller (barely 
detectable) IgE responses that were again transient, with ac- 
companying variable low titers of IgG. 
Parenteral Antigenic Challenge of Rats Preexposed to Antigen 
ANIMALS 
Naive 
1% OVA exposed 
Naive 
Naive 
TREATMENT 
AH/OVA 
AH/OVA 
10  6 undepleted splenocytes + AH/OVA 
from tolerant donors 
#10  6 CD8-depleted splenocytes + AH/OVA- 
from tolerant donors 
t  --t 
1'0  2'0  5  10  ;5 
RAST u/ml x 10  3  log  2 IgG titre 
Figure  2.  I  gE and IgG anti-OVA response in aerosol-exposed BN rats after intraperitoneal challenge with OVA in AH adjuvant. Data shown are 
peak titers as X  •  SD Rast U/ml (IgE) on day 9 and log2 IgG (as HA) on day 21 after challenge. (:) <controls by Student's t test, p <0.001. (#) Previous 
experiments indicate that depletion for CD3 + or CD5 § but not CD4 + cells abrogates adoptive transfer (9,  14). 
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specific IgE and IgG responses of naive BN rats with those 
preexposed to aerosolized  OVA once daily for 10 d. It can 
be seen that OVA-specific  IgE production in response to paren- 
teral  challenge was  markedly reduced in  aerosol-exposed 
animals. Comparable results (data not shown) were obtained 
with the WAG strain. Additionally, adoptive transfer of un- 
fractionated or CD8-enriched splenocytes from aerosol-exposed 
to naive animals, conferred a comparable state of hyporespon- 
siveness in the IgE Ab class, whereas depletion of T cells ex- 
pressing CD8 or CD5 abrogated this suppression (14 and 
Fig. 2). In contrast, adoptive transfer of suppression was not 
affected by the removal of CD4 + T cells from the donor in- 
oculum (14). 
In Vitro Activation and Cytokine Production by T Cells from 
Low and High IgE Responder Rats after In Vivo Antigen Chal- 
lenge.  Fig. 3 shows the kinetics of IL-4 and IFN-3, produc- 
tion after active immunization of low versus high IgE re- 
sponder rats, and dearly illustrates the reciprocal role of these 
cytokines in IgE regulation. Thus, the low-titer 1  ~ IgE re- 
sponse of WAG rats was associated with an early IL-2/IL-4 
response in the spleen and lymph nodes draining the site of 
antigenic challenge,  the IL-4 component being rapidly ter- 
minated with the onset of a wave of IFN-qr production. In 
contrast, BN rats demonstrated a sustained IL-2/IL-4 response, 
with no evidence of IFN-3' production during the first 14 d. 
The experiments of Fig. 4 examine in vitro T cell cytokine 
responses after repeated inhalation of low levels of antigen. 
Transient IgE production in the BNs (Fig. 1) was associated 
with the presence of antigen-specific  IL-4-secreting T cells 
(and low-level IL-2 activity) in the LNs draining the upper 
respiratory tract. In contrast, the low responder WAGs dis- 
played little or no specific IgE Ab, and cytokine production 
by OVA-activated T cells from these animals was restricted 
to IL-2/IFN-3,. 
After daily aerosol exposures for 1-2 wk followed by a 2-d 
"rest" period, the animals were subsequently reexposed to 
the aerosol once weekly for up to 6 mo (designated chronic 
exposure in Fig.  4).  Parenteral rechallenge with AH/OVA 
at any time during this period failed to elicit an IgE response 
in either strain,  as per Fig. 2. This state of selective "toler- 
ance" in the IgE Ab isotype was associated with the presence 
of OVA-specific IFN-'y secreting and IL-2-secreting T cells, 
the former restricted to the CD8-enriched population and 
the latter represented in both CD4 and CD8 populations. 
Parenteral rechallenge of tolerant animals produced variable 
degrees of boosting of both CD8 IL-2 and IFN-y activity 
in the low IgE responder strain. 
A limited series of experiments also examined the capacity 
of splenic T cells from parenterally  immunized and chroni- 
cally aerosol-exposed  BN rats  to respond to in vitro chal- 
lenge with OVA via proliferation and IL-2 release. Spleno- 
cytes from AH/OVA immunized rats taken during the early 
phase  of the  1  ~ IgE response proliferated vigorously and 
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Figure 3.  Cytokine production in high (BN) versus low (WAG) IgE responder animals after active immunization. Groups of rats (n  =  5) were 
immunized intraperitoneally with AH/OVA and LN (D) and spleen (m) removed on days 4, 9, and 14 after immunization. Cells were cultured in 
the presence of OVA (100/zg/ml) for 24 h, and supernatants were harvested and assayed for IL-2, IL-4, and IFN-3,. Results are expressed as X  _+ SD 
for triplicate measurements from a representative experiment  (n  =  3). Supernatants from control cultures (cells plus medium alone or the irrelevant 
Ag BSA) were negative. Subsequent examination of 48-h supernatants  (data not shown) did not alter interpretation of these results. 
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Figure  4.  Cytokine production in high (BAr) versus low (WAG) IgE responder  animals  after exposure to OVA  aerosols.  Groups of rats (n  =  5) 
were exposed daily to 1% OVA via inhalation  for varying periods up to 10 d. KTLN (1% OVA 1-4x) and pools of RTLN and spleen (other exposure 
periods) were removed 24 h after exposure indicated  and sorted into CD4-  (CD8 enriched)  (~)  and CDS-  (CD4 enriched)  (I)  populations.  All 
separated preparations contained g2%  negatively selected  cells.  The cells were cultured and assayed for cytokines as per Fig.  3. Results are expressed 
as X  _+  SD (triplicate  measurements) from a representative  experiment (n  =  3). 
released high levels of IL-2 after exposure to OVA (Table 1). 
OVA-specific responsiveness (albeit at a lower level) was also 
consistently seen in CD8-  splenocytes from aerosol-exposed 
rats,  in particular  after  rechallenge  of donor animals with 
AH/OVA, consistent with the presence of autonomous OVA- 
responsive  CD4 §  T  cells.  However,  both  CD4-  and  un- 
depleted splenocytes from the same animals were unrespon- 
sive  to  antigen,  suggesting  inhibition  of  CD4 +  T  cell 
proliferation and IL-2 release via a subset of the OVA-immune 
CD8 +  T  cell  population. 
Table  1.  Inhibition of OVA-specific CD4 +  T  Cell Proliferation and IL-2 Secretion In  Vitro by OVA-specific CD8 + T  Cells 
Cell  Proliferation 
Animals  population  (3H-DNA  synthesis)  IL-2  (U/ml) 
Normal  Undepleted  167,000  +_  6,379  12.0  _+  1.5 
plus  AH/OVA  CD4-  ND  ND 
challenge  CD8-  ND  ND 
Chronic  aerosol  Undepleted  873  _+  44  0.2  +  0 
exposure  *CD4-  41  _+  1  4.8  +  0.3 
(tolerant)  *CD8-  16,916  ___  807  1.25  _+  0.1 
Chronic  aerosol  Undepleted  4,121  _+  69  1.2  _+  0.1 
exposure  *CD4-  543  +_  32  7.0  _+  0.9 
plus  AH/OVA  *CD8-  33,606  _+  913  2.9  _+  0.6 
challenge 
Data is expressed as X  _+ SD. 
* g2%  contaminating CD4 +  or CD8 +  cells. 
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Figure 5.  Blocking  of antigen-specific IFN-3' production by CD4- 
splenocyte  using  mAbs against function-associated  surface  molecules.  Spleno- 
cytes from groups of BN rats (n  =  3) chronically exposed to 1% OVA- 
aerosol were sorted to yield a CD4- population (CD4 + contamination 
<1%), and stimulated in vitro with OVA as per Fig. 3. mAbs (as indi- 
cated) were added at 5 #g/ml to the culture.  Supernatants were assayed 
for IFN-'y as per Fig. 3. Superuatants from control cultures of cells with 
medium alone (no Ag), IL-2 alone (no_Ag), or irrelevant Ag (BSA) were 
all negative. Results are expressed as X  +_ SD (triplicate values) from a 
representative experiment  in a series of four. 
Interactions between MHC Class I- and lI-restricted T  Cells 
during the Response to OVA Antigen.  In Fig. 5, in vitro acti- 
vation of CD8-enriched splenocytes (containing <1% CD4 + 
T ceils) from aerosol-exposed OVA-tolerant BN rats was at- 
tempted in the presence of a range of mAbs directed against 
T cell function-associated surface molecules, using established 
protocols (20).  T  cell activation was assessed via measure- 
ment of IFN-y secretion into culture supernatants in the pres- 
ence of 100 #g/m1 OVA. IFN-y secretion was inhibited by 
mouse mAb against MHC dass I and II, CD4, and the high 
affinity  IL-2K,  but not by a control mAb  (OX21).  The 
blocking effects of anti-CD4 and anti-MHC class II (but not 
anti-MHC class I) mAb were significantly  reversed by the 
addition of 10 U/m1 rlL-2 to the cultures. 
Activation  of OVA-specific CD8 + T  Cells in Adoptive  Re- 
cipients.  As noted in Fig. 2, adoptive transfer of splenocytes 
from aerosol-exposed tolerant rats into syngeneic recipients 
confers a state of OVA-specific hyporesponsiveness analogous 
to that of the original donors, as evidenced by their failure 
to  develop  IgE  responses  after  parenteral  challenge with 
AH/OVA. It can be seen from Fig. 6 that in vitro stimula- 
tion ofT cells (in particular CD8 enriched) taken from animals 
2 d after adoptive transfer and in vivo challenge, reveals high 
levels of IL-2 and IFN-y secretion. 
Variable Representation of CD8 + OVA-specific T cells in the 
Pe@heral Blood of Low and High IgE Responder Rats after Toler- 
ance Induction.  The experiments in Fig. 7 examine the OVA 
reactivity of PBL from rats, after different forms of in vivo 
challenge.  In the low IgE responder WAGs, the peripheral 
blood clearly contained a significant population of OVA-specific 
IFN-3,  producing CD8 + T  cells, both in tolerant (aerosol 
exposed) animals and during the early stages of the primary 
immune response in naive animals (Fig.  7, d-f).  Tolerized 
BN  rats  in  contrast  demonstrated  no  detectable  IFN- 
"r-producing T cells, even after tolerance induction and sub- 
sequent parenteral rechaUenge (Fig. 7, a and b), but during 
the primary IgE response (Fig. 7 c) they demonstrated high 
levels of antigen-specific  IL-4 reactivity in peripheral blood 
which was attributable to CD4 + T  cells. 
Induction of  Antigen-specific IFN-7-producing  T Cells by OVA 
Feeding.  Stimulation of the gastrointestinal tract via antigen 
feeding induces a form of tolerance (known as oral tolerance) 
equivalent to that achieved by inhalation of much lower levels 
of aerosolized antigen. The experiments of Fig. 8 employed 
a standard protocol for oral tolerance induction in the rat, 
100 mg feeds of OVA administered by gavage on two con- 
secutive days, and the tolerant status of a parallel group of 
fed animals was confirmed by parenteral challenge (data not 
shown). Culture supernatants from OVA-stimulated CD4- 
and CD8-enriched T cells from the MLN of these animals, 
prepared 4 d after the last feed, demonstrated high levels of 
IFN-y activity. 
Discuss/on 
The state of antigen-specific hyporesponsiveness, which de- 
velops in experimental animals after exposure to inhaled pro- 
tein antigens, was originally described as a form of immuno- 
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Figure 6.  Cytokine production in T cells from adoptive 
recipients, after AH/OVA immunization. CD8 + splenocytes 
(98.8%  pure) prepared from aerosol-exposed tolerant  (BN) 
rats by positive selection  employing the OX8 mAb, were trans- 
ferred into naive recipients (106 cells/animal, n  =  5), con- 
comitant with All/OVA challenge. Splenocytes  were removed 
from the recipients 2 d after transfer and immunization, sepa- 
rated into CD8-enriched (I) and CD4-enriched ([]) subsets 
as per Fig. 4 and stimulated with OVA as per Fig. 3. Superna- 
rants were harvested and assayed for cytokines as per Fig. 3. 
Results  are  expressed as X  +-  SD  from  a  representative 
experiment. The tolerant status of a parallel group of adop- 
tive recipients was confirmed via AH/OVA challenge and as- 
sessment of serum IgE Ab, as per Fig. 2. Comparable data 
were also obtained employing CD4- splenocytes  prepared by 
negative selection for CD8 + (data not shown). 
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Figure 7.  Cytokine production by PBL from high (BN) 
and low (WAG) IgE responder rats after OVA exposure. PBL 
were prepared from group of rats (n  =  6) tolerant to OVA 
after chronic aerosol exposure  (a and d), tolerant and chal- 
lenged with AH/OVA (day 4 after challenge;  b and e), and 
AH/OVA-challenged naive animals (c and  f). Undepleted ([2]), 
CD8 enriched (VA), and CD4-enriched (I)  cells were pre- 
pared as per Fig. 4 and stimulated in vitro by OVA, and 24-h 
supernatants were harvested and assayed for cytokines as per 
Fig.  3.  Results  are X  _+  SD  of triplicate samples  from 
a representative  experiment. 
logical tolerance (21, 22), by analogy with the process of oral 
tolerance to fed antigens (23). Sensitivity to tolerogenesis via 
the respiratory tract was shown to be genetically determined 
(24, 25), and was variably selective for the IgE Ab isotype, 
the degree of selectivity also being related to genetic back- 
ground. Thus, acquired IgE hyporesponsiveness to inhaled 
antigen was usually  accompanied by suppression of corre- 
sponding delayed type hypersensitivity (DTH) reactivity (26), 
but apparently tolerized animals in several  rat and mouse strains 
manifested residual IgG and secretory IgA reactivity as well 
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Figure 8.  Cytokine production by MLN cells in normal versus OVA- 
fed WAG rats. Undepleted (f-]), CD8-enriched ([]), and CD4-enriched 
(,) cells were prepared from groups of three normal or OVA-fed (tolerant) 
animals, and cultured with OVA and assayed  for IFNw as per Fig. 3. Results 
are expressed as X  _+  SD of triplicate samples from a representative  ex- 
periment. 
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as antigen-responsive T cells in primary lymphoid organs (6, 
7). This tolerant state is accordingly more accurately described 
as a form of immune deviation. 
The present study sought to define the differences between 
the T cell responses of phenotypically high and low IgE re- 
sponder rats to inhaled OVA antigen, employing two strains 
that demonstrate 30-fold variations in the relative magnitude 
of their 1  ~ IgE responses to parenteral  antigenic challenge 
(Fig. 1, a and d). Consistent with recent data from other spe- 
cies (1, 2), these differences in IgE responder phenotype are 
reflected by the relative intensity of IFN-'y versus IL-4 produc- 
tion by OVA-specific T cells (Fig. 3). 
The relative magnitude of the IgE response to parenteral 
immunization is mirrored by the response to antigen inhala- 
tion. Thus, repeated exposure to aerosolized OVA resulted 
in transient  IgE Ab production in the high IgE responder 
BNs,  suggestive of an initial CD4 + Th2 response (Fig.  1, 
b and c), and OVA-specific IL-4-secreting CD8-  T  cells 
were concomitantly observed in the RTLN during this period 
(Fig. 4). A corresponding IgE response did not develop in 
the low IgE responder WAGs (Fig. 1, e and  f), but they in- 
stead demonstrated a vigorous IFN-3, response (Fig. 4) anal- 
ogous to their pattern of cytokine production after paren- 
teral immunization. 
The tolerant  state that developed after aerosol exposure, 
selective for IgE in the BNs (Fig. 2), but also encompassing 
IgG in WAGs (24), was associated with the presence of OVA- 
specific IL-2 secreting and IFN-3,-secreting T cells in lym- 
phoid organs (Fig. 4). IL-2-secreting activity was observed in both the CD4 ~ and CD8 § compartments, but IFN-3' ac- 
tivity was restricted to the enriched CD8 § T  cell popula- 
tion. Previous experiments have shown that tolerance in this 
model can be adoptively transferred with CD8 § T  cells (9, 
14), as illustrated also in the data in Fig. 2. Successful adop- 
tive transfer of tolerance was also associated with the devel- 
opment of this pattern of cytokine reactivity in T  cells of 
adoptive recipients (Fig. 6), but in this case, IL-2 production 
was more marked in the CD8 + population.  Additionally, 
low but significant levels of IFN-y-secreting activity were 
observed in CD4 + T  cells of the adoptive recipients after 
parenteral challenge (Fig.  6), suggesting a growing contri- 
bution  from the CD4 +  Thl  T  cell compartment to  the 
overall IFN-y response, driven by restimulation with antigen. 
The experiments in Fig. 5 address the important issue of 
MHC restriction of the regulatory T  cell response in this 
model, and highlight the role of exogenous IL-2 in initiation 
of CD8 + T  cell activation. MHC class II-restricted CD8 + 
T  cells have recently been implicated in other systems (27), 
including those that are specific for OVA antigen (28). How- 
ever, the profound inhibition of OVA-induced IFN-3~ secre- 
tion by CD8-enriched splenocytes from the aerosol-exposed 
animals by anti-class I mAb (Fig. 5) suggests the effector cells 
here are classical MHC class I-restricted CD8 + T cells. Not- 
withstanding this result, the finding of equivalent levels of 
blocking of antigen-induced IFN-3, secretion by mAbs against 
MHC class II, CD4, and high-affinity IL-2R imply that ad- 
ditional  signals  are required for activation of these CD8 + 
cells. 
As noted in the figure legends, these CD8-enriched cell 
preparations were contaminated with up to 2%  CD4 + T 
cells, and the inhibitory activity of anti-CD4 and anti-class 
II mAbs, together with the demonstration of reversal of this 
inhibition with rlL-2, suggest an obligatory contribution from 
OVA-responsive IL-2-secreting CD4 + T cells in the activa- 
tion of the CD8 + population.  This is consistent with re- 
cent reports on the dependence of some MHC class I-restricted 
CD8 § T  cells on IL-2 from CD4 + T  cells during primary 
activation (29, 30), in particular under conditions of subop- 
timal stimulation (29).  This appears  to be particularly the 
case in rats, where CD4 § contamination levels as low as 1% 
appear sufficient to provide the permissive IL-2 signal required 
during the initial phase of in vitro CD8 + activation (30). 
However, once the OVA-specific CD8 + T cell response has 
been initiated and appropriately boosted in this system, au- 
tocrine production of IL-2 by the CD8 + population, evident 
in the data of both Figs.  4 and 6, obviates the requirement 
for the CD4 T  cells. 
We have not been able to demonstrate OVA-induced in 
vitro proliferation of CD8 § T cells in this system, including 
with the chronically exposed animals illustrated in Fig.  4. 
Moreover, as shown in Table 1, chronically exposed animals 
contained OVA-specific T cells that were capable of prolifer- 
ation and IL-2 release, but this capacity was inhibited in the 
presence of CD8 + T  cells.  The same CD8 + T  cells were 
clearly capable of IL-2 release themselves, so it is unlikely 
that the lack of IL-2 per se was the factor limiting CD4 § 
T  cell proliferation. The underlying mechanism(s) are cur- 
rently under separate investigation in our laboratory. 
Implicit in our interpretation of the data presented above 
is the suggestion that MHC class I-restricted CD8 + T ceils 
can be primed and subsequently reactivated, in response to 
low levels of inhaled soluble OVA antigen. Until recently, 
it was believed that the exclusion of soluble antigens from 
the MHC class I pathway of antigen presentation was abso- 
lute. However, it is now clear that the cytoplasm of APCs 
can be "loaded" in vitro with soluble protein antigens by 
pulsing in either hypertonic or isotonic medium, effectively 
charging surface class I molecules with sufficient processed 
antigen for CD8 + T  cell priming (31-34). 
The present model argues this process can also occur under 
normal conditions in vivo, in response to low levels of soluble 
antigen impacting upon the respiratory mucosa, and earlier 
dose-response data from this model (24,  25) imply that in 
certain strains of mice and rats the threshold levels of inhaled 
antigen required for initiating such CD8 + responses is in the 
nanogram zone. An additional precedent for this thesis are 
recent reports indicating in vivo activation of antigen-specific 
CD8 + T  cells that mediate adoptive transfer of oral toler- 
ance, via feeding soluble OVA (35).  It is pertinent to note 
that the rats fed with a tolerogenic dose of OVA in the present 
experiments also demonstrated IFN-3~-secreting OVA-specific 
T  cells in the LNs draining the gastrointestinal tract (GIT) 
(Fig. 8). In this situation, the concentration of antigen avail- 
able in the microenvironment of the gastric mucosal APCs 
would also be extremely low, particularly in the experiments 
described by Miller et al. (35) where oral tolerance mediated 
by CD8 + T cells was induced by repeated feeds of only 1.0 
mg OVA. 
In  relation  to  the  respiratory  tract,  we  have  recently 
identified dendritic cells as the principal resident professional 
APC population,  where they form a network throughout 
the alveolar septa  and the airway epithelium (36,  37).  We 
have further demonstrated that OVA inhalation effectively 
charges their MHC class II molecules with sufficient OVA 
peptide  to  activate CD4 ~ T  cells  (38-40).  We do not  at 
present have data on the capacity of the airway intraepithelial 
dendritic cells to present inhaled OVA antigen via the class 
I pathway. However, the demonstration of the unique potency 
of dendritic cells as APCs for MHC class I-restricted CD8 + 
T cells in other systems (29, 41) suggests they are likely can- 
didates for this role. The situation in the GIT may be more 
complex as a wider range of potential APCs appears available 
for T  cell priming, which may account for the differences 
in the relative contribution of CD4 § T  cells to the overall 
T cell-mediated IFN-3~ response in OVA-fed versus aerosol- 
exposed animals (cf.  Figs.  4  and 8). 
The data presented above  thus suggests a novel control 
mechanism for protection against the development of CD4 + 
Th2-mediated allergic reactivity to inhaled nonreplicating an- 
tigens, i.e., deviation of the host response away from the Th2 
phenotype  via  the  creation  of a  cytokine milieu  rich  in 
CD8 +  T  cell-derived  IFN-%  which  selects  against  the 
growth of Th2 clones during the early phase of the immune 
896  IgE  Regulation  via CD8 § T  Cell-mediated Immune Deviation response (42, 43). Whereas such a mechanism potentially ex- 
plains overall suppression of IgE responses to inhaled antigens 
in these two strains, there are a series of key questions which 
remain unanswered, in particular concerning the basis for the 
genetically determined  differences in threshold  inhaled an- 
tigen dosage required to induce this form of immune devia- 
tion (24, 25). Additionally,  the fact that DTH reactivity is 
suppressed along with IgE responsiveness in the WAG strain 
but not in the BN (26), suggests that cytokines other than 
IFN-3, may also play a role in the process.  It is of interest 
to note in this regard that blocking Abs against both IFN-3, 
(44) and TGF-~ (45) have independently been shown to ab- 
rogate oral tolerance. 
The degree to which this form of acquired immune devia- 
tion modulates the human immune response to airborne en- 
vironmental antigens, remains to be established. In approaching 
the question,  it is important  to note that  the key element 
of this animal model of acquired tolerance, is its applicability 
to only the initial stages of the immune response in the naive 
host,  i.e.,  it  has not been possible to deviate ongoing  IgE 
responses in animals with an established CD4 + T-memory 
population. 
In this context, it is now generally conceded that primary 
T cell sensitization to environmental antigens in humans most 
commonly occurs in early infancy, when the majority of such 
antigens are first  encountered (46). Transient  low-level IgE 
serum Ab production  to both inhalant  and food antigens, 
analogous to those described in the model above, are now 
recognized to occur in normal nonatopic children (46), sug- 
gesting the initial development of CD4" Th2-1ike responses 
to these antigens which (with continued exposure) are even- 
tually suppressed.  However, the published data on human 
T cell reactivity to environmental antigens relates exclusively 
to PBL from chronically stimulated adults, where the only 
detectable antigen-specific T  cells are reportedly CD4 + Th2 
(in  atopics)  and  CD4 + Thl  (in  nonatopic  normals).  The 
latter T cell populations would thus have undergone repeated 
stimulation and selection over a period of years,  which may 
obscure more subtle mechanism(s) operative during priming. 
In particular,  antigen-specific IFN-'y-secreting CD8 + T 
cells may create a milieu that favors the slow outgrowth of 
IFN-3,-secreting  CD4 +  Thl  T  cells  which,  by virtue  of 
their  greater inherent  capacity for proliferation,  eventually 
supplant  the CD8 + population.  This possibility is consis- 
tent with the animal data of Fig.  6, demonstrating  the de 
novo appearance of antigen-specific IFN-3,-secreting CD4 + 
T  cells  in  this  system only after  adoptive transfer  and re- 
stimulation in the recipients.  It is also likely that PBL pro- 
vide an imperfect window on the human CD8 + T  cell re- 
sponse.  The  recirculation  properties  of CD8 + T-memory 
cells are poorly understood, and it is evident from the data 
in Fig. 7 that the degree of representation of antigen-specific 
CD8 +  T  cells  in  PBL  varies  markedly  between  animal 
strains.  Primary lymphoid organs (such as tonsils) may pro- 
vide more appropriate T cell populations for similar studies 
in humans,  and this approach is currently being followed in 
our laboratory. 
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